To report the emergence of the new designer benzodiazepine ethylbromazolam and assess its pharmacological activity, highlighting its potential impact on public health.
Key Findings:
Ethylbromazolam has emerged in Canada, the UK, Australia, and Germany as a new DBZD, raising concerns about its impact on public health.
It is a close analog of bromazolam, differing by an ethyl group on the triazole ring, which may influence its pharmacological profile.
DBZDs, including ethylbromazolam, act as positive allosteric modulators of the GABAA receptor, potentially leading to significant health risks.
Interpretation:
The rise of ethylbromazolam reflects ongoing trends in the designer drug market, particularly in response to regulatory changes affecting other DBZDs, necessitating further investigation.
Limitations:
The study is limited to specific geographic regions and may not represent global trends, and potential biases in drug checking analysis could affect results.
The pharmacological effects of ethylbromazolam in humans remain to be fully characterized, highlighting the need for further research.
Conclusion:
Ethylbromazolam represents a significant addition to the DBZD landscape, necessitating urgent research on its effects and implications for public health.
by Caitlyn Norman, Dean Acreman, Meera Bissram, Blake Curtis, Sebastian Hamer, Folker Westphal, Michael Putz, Cristiana Stefan, Sarah R. Delaney, Rick Lines, Malcolm D. McLeod, Karen McDonald, Henrik Green
